Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...

Cytogenetic risk doesn't seem to explain the disparity in mortality of Black vs White patients, a study across 10 clinical ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...

Black race, regardless of cytogenetics, was found to be associated with poorer survival in a 30-year retrospective analysis of clinical trials involving patients with acute myeloid leukemia (AML) ...

Venclexta-azacitidine combination offered better responses with less hospitalization and lower symptom burden compared with ...

SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in ...